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Breast angiosarcomas (AS) are rare malignant endothelial cell
tumours of vascular or lymphatic origin [1]. They account for less
than 1% of all breast malignancies [2] and are poorly understood.
Angiosarcomas may develop spontaneously as a primary malig-
nancies, often in younger women between the ages of 20–40 or
occur secondary to chronic lymphoedema (Stewart-Treves Syn-
drome) or radiotherapy in women who have undergone treatment
for breast cancer [3,4].
Primary angiosarcomas arise de novo, occurring most com-
monly in the head and neck area as cutaneous lesions, followed
by the breasts and extremities [1]. Primary breast angiosarcomas
are found to tend towards the development of metastases, whereas
secondary cases show a high local recurrence rate. Regardless of
subtype, the overall outlook is similarly bleak [5].
Radiotherapy associated angiosarcoma (RAAS) is a rare, but
established complication of treatment for early breast cancer.
Defined as the development of a sarcoma in a previous radiotherapy
field with a latency period of at least three years [6], its aetiology
and precise relation to the radiotherapy given is poorly understood:
The incidence of RAAS is estimated at between 0.04 and 0.18% [7] in
women treated with radiotherapy and although this does not
appear to be influenced by the type of surgery performed (mastec-
tomy or wide local excision), there may be a potential interaction of
radiotherapy and lymphoedema following treatment [8]. There
may also be a dose response relationship between the dose of radio-
therapy given and the incidence of RAAS with a minimum of 10 Gy
associatedwith the development of the condition (but usually asso-
ciated with higher doses) [9]. The impact of new techniques such as
intensity modulated radiotherapy or hypofractionation are unclear
and further study is needed [8].
Data on the optimal management and subsequent prognosis of
RAAS is similarly lacking [8,9]. While surgery remains the mainstayof treatment, local recurrence rates range from 54 to 92% and the
addition of further radiotherapy with or without hypothermia
has been investigated in several small studies and may be benefi-
cial [8,9]. Chemotherapy with taxanes or other agents targeted
against vascular endothelial growth factor (VEGF) or components
of the Ret proto-oncogene (RET) signalling pathway recently found
to be upregulated (V-myc myelocytomatosis viral oncogene homo-
logue (MYC), V-Kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homologue(KIT) and RET) or downregulated ((cyclinde-
pendent kinase inhibitor 2C (CDKN2C)) specifically in secondary
angiosarcoma may also be valuable [10] although so far results
of such approaches have been disappointing [11].
Data on prognostic factors is similarly lacking although five year
survival is poor ranging from 27 to 43% in two recent systematic
reviews [8,9]. These reviews, however, are based on small, single
centre largely retrospective studies published between 1970 and
2013 with inconsistent definitions and outcomes which are unli-
kely to reflect current practice. This is particularly important given
that wide local excision and radiotherapy has become the standard
of care for early breast cancer and the incidence of RAAS may be
increasing.
Knowing how to adequately manage these tumours is impera-
tive, however there is currently no conclusive or valuable evidence
looking specifically at breast sarcomas to guide surgical manage-
ment. Much of the current proposals are derived from either small
retrospective case reviews or extrapolated from non-breast sar-
coma studies. Furthermore, a lot of the recent data consider breast
sarcomas as a whole, despite the fact angiosarcomas can behave
differently, with the survival rate of the latter being 40% lower
[12]. Attention has recently been focused on how we might make
outcomes for patients with rare tumours better, and argument
has been made towards managing such cancers within a specialist
centre, to allow greater access to specialist services in pathology
and highly specialised Multi-Disciplinary Expert Panels [13]. There
is evidence to suggest that improved adherence to specific guideli-
nes can improve outcomes for sarcomas, especially when applied
in referral centres [14].
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heterogeneously between the plastic, oncology and breast teams.
We wish to review current practice and outcomes with a view to
better understanding this disease and furthermore, improve care.
Due to small numbers involved it is difficult to collate adequate
data regarding this patient group within one centre, and a more
cohesive, collaborative approach is required.
There is therefore a need to collect high-quality contemporane-
ous data regarding the current incidence and management of both
primary breast AS and RAAS to describe variations in practice and
inform the design of future prospective studies.
The challenges to the design and conduct of large-scale cohort
studies are well-documented, but the trainee collaborative model
has emerged as a time and cost-effective means of delivering
high-quality prospective research and audit [15–20]. The iBRA
study [21], a national audit of the practice and outcomes of
implant-based breast surgery has demonstrated the model is
transferable to breast and plastic surgery and has established a
network of centres willing and able to participate in future pro-
jects. It is hypothesised that this network of highly-motivated
and enthusiastic breast and plastic surgical trainees and consul-
tants can be utilised to deliver further high-quality audits in breast
and reconstructive surgery.2. Methods and analysis
2.1. Aims and objectives
BRASS aims to use the trainee collaborative model to
Describe the current practice in diagnosis, staging and manage-
ment of primary breast and secondary AS in relation to the
National Comprehensive Cancer Network (NCCN) Clinical Practice
Guidelines in Oncology Soft Tissue Sarcoma [22].
Evaluate the outcomes of patients treated for primary breast
and secondary AS in the UK and describe prognostic factors.
Generate data to help guide best practice guidelines in the
future.
To inform a potential prospective study of primary breast AS
and RAAS.2.2. Definition
Radiation associated angiosarcoma of the breast will be defined
as
 an angiosarcoma occurring in the breast or chest wall (if previ-
ous mastectomy) following previous diagnosis and treatment
with radiotherapy of breast cancer.
2.3. Hypothesis
Breast angiosarcoma is managed according to NCCN guidelines
[22] for soft tissue sarcoma within the UK. Despite this, recurrence
rates remain high (54–92%) and outcomes are poor with 5 year
survival quoted as being as low as 27–43% [8,9].2.4. Study design
This is a trainee-led retrospective multicentre audit co-
ordinated by members of the BRASS steering group supported by
members of the Mammary Fold Academic and Research Collabora-
tive (MFAC) and the Reconstructive Surgery Trials Network (RSTN).2.5. Setting
All breast and plastic surgery units in the UK treating angiosar-
coma of the breast or chest wall will be eligible to participate in the
study. Trainees from across the UK will be invited to participate in
the study through the Mammary Fold, the RSTN and, the National
Research Collaborative network. Support will also be sought from
the professional associations, the Association of Breast Surgery
(ABS) and the British Association of Plastic, Reconstructive and
Aesthetic Surgery (BAPRAS).
The study will be piloted in five centres; Liverpool, Exeter, Bath,
Leeds and Birmingham (chosen as interested parties already
engaged with the project residing in these centres) prior to
national roll-out of the audit to evaluate the feasibility of trainees
being able to identify appropriate patients and collect the neces-
sary data (‘successful pilot’ defined as the identification and entry
of a single whole patient data set). The pilot will also be used to
test the acceptability and feasibility of on-line data collection using
the REDCap database and modify the pro-formas as needed prior to
national roll-out.
2.6. Participants
2.6.1. Inclusion criteria
All patients (male and female) over the age of 16 years with a
histologically confirmed diagnosis of primary or secondary
angiosarcoma of the breast, skin overlying the breast or anterior
chest wall between 1st January 2000 and the 31st December 2015.
2.6.2. Exclusion criteria
Patients without a confirmed tissue diagnosis of primary breast
AS or RAAS.
2.7. Outcome measures
The primary outcome measures include the percentage of
patients undergoing diagnostic biopsy, cross sectional imaging
and whom are discussed at an appropriate multidisciplinary team.
These are based on the standards for the management of soft tissue
sarcoma from the National Comprehensive Cancer Network
(NCCN) [22].
Data regarding adequate oncological margin clearance for
resectable disease and rates of recurrence (local and metastatic)
will also be collected (Table 1).
Data fields for BRASS (Table 2).
Data will be recorded anonymously using a study identification
number on a secure web based database. Though the data set for
collection is extensive, the number of patients per centre is antic-
ipated to be small. The data form will be trialled across the pilot
centres prior to national roll-out and amended as necessary based
on feedback received. This will ensure the data collection form is
acceptable and complete prior to initiation of the main study.
2.8. Data validation and management
Following data collection, a random selection of approximately
5% of data sets will be selected. The principal investigator at the
identified centres will be contacted and asked to independently
validate a proportion of the data. If concordance is <80%, a further
data sample will be selected. If concordance remains <80%, the cen-
tre will be excluded from the analysis.
Data collection will remain in accordance with Caldicott II prin-
ciples. Data for each patient will be anonymised using a unique
alphanumeric study identification number. Local collaborators will
be asked to keep a spreadsheet linking hospital number to study
number to prevent duplication of entries. This should be stored
Table 1
Outcome measures.
Outcome measure Definition
Sarcoma MDT referral rate All patients (100%) should be evaluated by a multidisciplinary team with experience of sarcoma
Core or incisional biopsy rate All patients should have a biopsy (core or incisional) to establish grade and histological sub-type
Cross sectional imaging rate All patients should have cross-sectional imaging (MRI ± CT) to provide details of tumour size, relationship to nearby visceral
structures and neurovascular landmarks
Resectable disease: Margin
clearance
Surgical excision should be performed with adequate oncological radial margin (usually greater than 10 mm)
Non-resectable disease:
Chemotherapy offered
Patients should be considered for palliative chemotherapy or neoadjuvant chemotherapy in view of potentially improving
surgical treatment options
Recurrence rate Rate of recurrence (local and metastatic) following initial treatment
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No patient identifiable data will be recorded for the purpose of this
audit. No formal training is required for those collecting data.
Study data will be collected and managed using REDCap elec-
tronic data capture tools hosted at the University of Oxford. RED-
Cap (Research Electronic Data Capture) is a secure, web-based
application designed to support data capture for research studies,
providing 1) an intuitive interface for validated data entry; 2) audit
trails for tracking data manipulation and export procedures; 3)
automated export procedures for seamless data downloads to
common statistical packages; and 4) procedures for importing data
from external sources [23].
2.9. Anticipated recruitment
Based on experience from the iBRA study [24] approximately
40% of centres will participate in the study. There are 144 breast
units within the UK. Scoping work in one pilot centre (Exeter) sug-
gests that approximately 10 cases may be anticipated per centre
over the 15 year period. We would therefore expect to collect data
on approximately 570 cases which would be the largest series in
the literature, with current retrospective series ranging from 1 to
160 cases [8]. This figure is flexible, and derived in order to give
an estimate of anticipated recruitment. Regardless of total num-
bers the study will remain valid, as it will remain the first national
collation of data of its kind.
2.10. Study timelines
November-January 2016/2017: Local pilot centre data collec-
tion, refinement of data collection forms and on-line database to
optimise acceptability.
February–March 2017: Registrations of interest from plastic or
breast surgery units. Completion of local audit approvals.
April 2017–June 2017: Main study data collection.
July–August 2017: data validation.
September 2017: Data analysis and dissemination.
2.11. Statistical analysis
All data analysis will occur centrally, with the support of statis-
ticians and methodologists at the University of Liverpool Clinical
Trials Research Centre.
Simple summary statistics will be calculated for each outcome
and regression analysis used to control for confounding variables.
Predictors for adverse outcomes will be explored.
3. Discussion
Angiosarcoma of the breast remains a significant management
challenge as local recurrence rates are high and five year survivalpoor. Furthermore there are concerns that the incidence of sec-
ondary RA may be increasing as wide local excision and radiother-
apy is now the standard of care for early breast cancer unless
contraindicated [25].
There is a therefore need for high-quality outcome data to
inform best practice and guide future research to benefit patients.
The current evidence, however, is based on small single centre
heterogeneous case series which cannot meaningfully be com-
pared or combined. The BRASS study will collect standardised out-
come data on a large cohort of patients with primary and
secondary AS. This will be an incredibly powerful dataset which
will allow prognostic factors to be meaningfully explored to pro-
vide better information for patients and multidisciplinary teams
involved in their care. It is also hoped that the insights generated
from the BRASS cohort will inform future research and ultimately
allow outcomes for patients to be improved. The use of trainee col-
laborative methodology will ensure the study is completed in a
time and cost-effective manner and further consolidate the infras-
tructure created by the iBRA studies and TeaM [21,26] It is antici-
pated that the BRASS study will grow this network by engaging
oncology and pathology trainees to create capacity for future
research.
The BRASS study has limitations which require consideration.
This is a retrospective study with risks of missing and incomplete
data. Angiosarcoma, however is rare and a retrospective review
provides the opportunity collect standardised data on a large
cohort of patients. This will allow exploratory analyses to be
undertaken and therefore represents an excellent starting point
for future research. The dataset is complex which may further
increase the risk of missing data and reduce the value of the study.
The data collection pro-formas however will be rigorously piloted
in several centres to ensure they are complete and user friendly
prior to roll out of the main study. Data logic will also be used to
ensure that only relevant fields are displayed during data entry,
minimising the workload for collaborators. Finally, the manage-
ment of the condition may have changed over the 15 year study
period. While this is an important consideration, the data gener-
ated from the BRASS study will be valuable in helping to provide
a better understanding of the patterns of disease. This may inform
management and lead to novel research strategies which will ulti-
mately benefit patients.Ethics and dissemination
Patient care will in no way be affected by this study. Therefore
research ethics approval is not required, as confirmed by the
Health Research Authority (HRA) online decision tool. (www.Hra-
decisiontools.org.uk/research). Local audit approvals will need to
be obtained, with a supervising named consultant, if the unit lead
is a trainee. This approval will be collected by the BRASS team,
Table 2
Data fields for BRASS.
Field Options
Section 1: Patient demographics
Sex Male/Female
Age at diagnosis of breast cancer (if
relevant)
Age in years
Age at diagnosis of AS Age in years
Smoking status Nonsmoker/smoker/ex-smoker
Medical co-morbidities:
At time of diagnosis of breast
cancer (if RAAS)
At time of diagnosis of AS (if
primary AS)
Free text
Section 2: Breast cancer treatment data
Date of diagnosis (date of diagnostic
biopsy)
DD/MM/YY
Side Right/left/bilateral
Date of final breast surgery DD/MM/YY
Final surgery performed to breast (WLE/Mastectomy only/
Mastectomy and breast
reconstruction/ Therapeutic
mammoplasty)
Final surgery performed to axilla Axillary sample/sentinel node
biopsy/axillary dissection or
clearance/ none
Breast cancer histology data
Type of lesion Invasive ductal/ invasive lobular/
LCIS/DCIS/Mixed/Other: Specify
Grade 1–3
Low-High
Single or Multifocal (if multifocal
enter worst diagnosis for following
fields)
Single/Multifocal
Size of invasive lesion In millimetres
Total size of whole lesion including
DCIS, if any
In millimetres
Number of involved lymph nodes Number
Total number of lymph nodes in
specimen
Number
Receptor status ER:Positive/negative/not known
PR: Positive/negative/not known
HER2: Positive/negative/not known
Lymphovascular invasion Yes/No
Closest radial margin In millimetres
Breast cancer adjuvant therapy details
Intraoperative radiotherapy to breast
or chest wall?
Yes/No
If yes: Dose Dose in Gy and Energy
External beam radiotherapy to breast
or chest wall?
Yes/No
Dose In Gy and energy
Number of fractions Number
Treated daily Yes/No
Date radiotherapy started DD/MM/YY
Date radiotherapy completed DD/MM/YY
Axilla treated with radiotherapy? Yes/No
Supraclavicular fossa treated with
radiotherapy?
Yes/No
Was a Boost given? Yes/No
Boost Electrons Energy – MeV
Boost Megavoltage Energy – MeV
Boost Orthovoltage Energy kV
Boost Dose Gy
Boost Number of fractions Number
Did the patient receive
chemotherapy?
Yes/No/Don’t know
Chemotherapy: regimen given Free text
Chemotherapy: Start date DD/MM/YY
Chemotherapy: End date DD/MM/YY
Was the patient treated with
Herceptin?
Yes/No
Herceptin: start date DD/MM/YY
Herceptin: end date DD/MM/YY
Was the patient treated with
endocrine therapy?
Yes/No
Table 2 (continued)
Field Options
Which endocrine agent was used Tamoxifen
Aromatase inhibitor (specify)
Other: specify
Endocrine therapy start date DD/MM/YY
Endocrine therapy end date DD/MM/YY
Breast cancer clinical follow up
If the patient was followed up in
clinic, were any of the following
post- radiotherapy changes noted?
Thickening of skin Yes/No
Lymphoedema of the breast Yes/No
Lymphoedema of the arm Yes/No
Date of last mammogram prior to the
diagnosis of angiosarcoma
DD/MM/YY
Section 3: Angiosarcoma (AS) Data
Date of diagnosis (diagnostic biopsy) DD/MM/YY
Location of tumour Free Text
AS: Route of diagnosis
Clinical presentation Visible (cutaneous)/Palpable/
Radiological
Medical photography undertaken Yes/No/Don’t know
Histology: FNA Yes: give details of report (free text)/
No
Histology: Punch biopsy Yes: give details of report (free text)/
No
Histology: Excision biopsy Yes: give details of report (free text)/
No
Imaging: Mammogram Yes: Give findings/ No
Imaging: USS Breast/Axilla Yes: Give findings/ No
Imaging: CT Thorax/Abdomen Yes: Give findings/ No
Imaging: MRI Yes: anatomical region, findings/ No
Imaging: Other (e.g. PET) Yes: anatomical region, findings/ No
Was the patient discussed at a
sarcoma MDT?
Yes/No
Was the patient discussed at a breast
MDT?
Yes/No
Stage at diagnosis Tumour: T1a/T1b/T2a/T2b
Lymph nodes: N0/N1
Metastasis: M0/M1
Was tumour considered resectable? Resectable/Non-resectable/Not
known
Metastatic disease at presentation? Yes; specify site/No
AS: Management
Lead care provider Local cancer centre/ Regional
sarcoma centre
If regional sarcoma centre led care,
which specialty led the patients
follow up?
Surgery/Oncology/Joint
Lead surgeon specialty Breast/Plastic/Sarcoma
Lead oncologist sub-specialty interest Breast/Sarcoma/Unknown
Management involved surgery Yes/No
Type of operation performed Wide local excision/Mastectomy/
Wide local excision plus autologous
reconstruction/ Mastectomy plus
autologous reconstruction/
Mastectomy plus implant
reconstruction
Post-operative complications? Yes: Flap loss/ Yes: Poor healing/
Yes: Other; specify/ No
AS: Histology
Is tissue banked? Yes/No/Don’t know
Size of tumour Size in mm
Grade 1 - low/ 2/ 3 -high
Tumour markers: CD31 Positive/Negative/Don’t know/Not
performed
Tumour markers: CD34 Positive/Negative/Don’t know/Not
performed
Tumour markers: C-myc Positive/Negative/Don’t know/Not
performed
Tumour markers: Other IHC Yes: give details/ No
Distance to margins: Superior,
Inferior, Medial, Lateral, Posterior
Distance in Mm
Excision deemed adequate? Yes/No/Don’t know
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Table 2 (continued)
Field Options
AS: Adjuvant therapy
Patient received chemotherapy Yes/No/Don’t know
Chemotherapy regimen Free text
Chemotherapy start date DD/MM/YY
Chemotherapy end date DD/MM/YY
Patient received biological therapy? Yes/No/Don’t know
Biological agent used Free text
Biological therapy start date DD/MM/YY
Biological therapy end date DD/MM/YY
Patient received Electrochemotherapy Yes/No/Don’t know
Electrochemotherapy regimen Free text
Date of Electrochemotherapy DD/MM/YY
Patient received external beam
radiotherapy?
Yes/No/Don’t know
Radiotherapy dose Gy/Energy
Number of fractions Free text
Section 4: Follow up surveillance
Recurrence Yes/No
Date of recurrence DD/MM/YY
Type of recurrence Local/Metastatic; give location
Management of recurrence
Details of surgical management Free text
Closest margin of re-excision mm
Chemotherapy used for recurrence? Yes/No
Chemotherapy: Regimen Free text
Chemotherapy: Start date DD/MM/YY
Chemotherapy: End date DD/MM/YY
Other salvage treatments used? Yes; detail/ No
Further recurrence? Yes (Repeat section 4 thus far)/No
Outcome
Patient deceased? Yes/No
Cause of death Free text
Last patient contact MM/YY
Last imaging date MM/YY
Imaging modality CT/MRI/Plain film
Imaging site Free text
Imaging result Free text
J. Banks et al. / International Journal of Surgery Protocols 5 (2017) 5–10 9prior to the commencement of data collection. Patient consent is
not required as no patient identifiable data is being recorded.
Dissemination of the protocol will be via national trainee col-
laborative groups: The Reconstructive Surgery Trials Network
(RSTN) and the Mammary Fold Breast Trainee Group Academic
and Research Collaborative (MFAC). Individual centres will have
access to their own data, and data will be fed back to participating
centres at the end of the study.
Results of the study will be presented at scientific meetings and
published in peer-reviewed journals.
The study report will be prepared according to the STROBE
(Strengthening the Reporting of Observational Studies in Epidemi-
ology) reporting guidelines for observational studies [27].
The BRASS project is registered with ResearchRegistry.com,
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